Migraine

Your daily dose of the clinical news you may have missed.

Your daily dose of the clinical news you may have missed.

An analysis of patient reported outcome measures from 3 pivotal phase 3 RCTs of atogepant 60 mg demonstrates efficacy across functional domains as well as for migraine prevention.

The CGRP inhibitor fremanezumab reduced both monthly migraine and monthly headache days among children aged 6 to 17 years with a favorable safety profile.

Your daily dose of the clinical news you may have missed.

A single 750 mg intravenous infusion of Lu AG09222 showed a 2-day difference in reducing monthly migraine day compared with placebo.

Use of the unique STS101 drug device combination proved safe, well tolerated, and effective with as needed use over 12 months, reported Satsuma Pharmaceuticals.

Help young patients with migraine (and their parents) get and stay prepared for the shift from home to college with this migraine survival kit checklist.

Your daily dose of the clinical news you may have missed.

Erenumab 140 mg safely and effectively induced remission in nonopioid MOH within 6 months in individuals for whom other preventive medications had failed.